Compare Chubb Ltd (CB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chubb Ltd vs TransMedics Group Inc — how do they compare? Chubb Ltd trades at $344.11 (market cap $133.90B), while TransMedics Group Inc trades at $88.01 (market cap $3.10B). The key difference: Chubb Ltd is far larger — about 43.2× TransMedics Group Inc's market cap, and Chubb Ltd pays a 1.18% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| CB | TMDX | |
|---|---|---|
Market Cap | $133.90B | $3.10B |
Sector | Financials | Technology |
52-Week High | $363.50 | $150.42 |
52-Week Low | $268.20 | $61.99 |
Enterprise Value | $154.74B | $3.49B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chubb Limited (CB) trades at $343.12, down 1.49% on the day, with a neutral technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $7.26 versus $6.77 expected, and a net income margin of 17.96% for 2025. Revenue has grown from $43.1B in 2022 to $59.8B in 2025, with further growth projected. A recent dividend of $1.02 was declared for H1-26, payable July 2, 2026.
The outlook remains positive given analyst consensus favoring Buy ratings (52.38%) and a price target of $366.83, implying ~7% upside. Risks include potential volatility from macroeconomic factors and competitive pressures in the insurance sector. The company’s disciplined underwriting and investment income growth support long-term value, but investors should weigh valuation multiples against sector peers.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
